This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2001 Feb 24;357(9256):574-5.

doi: 10.1016/S0140-6736(00)04075-7.

Rigorous detection and vigorous treatment of familial hypercholesterolaemia

P N Durrington¹

Affiliations

PMID: 11558479
DOI: 10.1016/S0140-6736(00)04075-7

Comment

Rigorous detection and vigorous treatment of familial hypercholesterolaemia

P N Durrington. Lancet. 2001.

. 2001 Feb 24;357(9256):574-5.

doi: 10.1016/S0140-6736(00)04075-7.

Author

P N Durrington¹

Affiliation

¹ University of Manchester Clinical Research Division II, Manchester Royal Infirmary, UK. pdurrington@hq.cmht.nwest.nhs.uk

PMID: 11558479
DOI: 10.1016/S0140-6736(00)04075-7

No abstract available

PubMed Disclaimer

Comment in

Measurement of atherosclerosis progression.
Wierzbicki AS, Crook MA, Reynolds TM, Mikhalidis DP. Wierzbicki AS, et al. Lancet. 2001 Jul 28;358(9278):329-30. doi: 10.1016/s0140-6736(01)05503-9. Lancet. 2001. PMID: 11501530 No abstract available.

Comment on

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.
Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Smilde TJ, et al. Lancet. 2001 Feb 24;357(9256):577-81. doi: 10.1016/s0140-6736(00)04053-8. Lancet. 2001. PMID: 11558482 Clinical Trial.

Similar articles

Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial.
Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Smilde TJ, et al. Lancet. 2001 Feb 24;357(9256):577-81. doi: 10.1016/s0140-6736(00)04053-8. Lancet. 2001. PMID: 11558482 Clinical Trial.
High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia.
Wierzbicki AS, Lumb PJ, Semra YK, Crook MA. Wierzbicki AS, et al. QJM. 1998 Apr;91(4):291-4. doi: 10.1093/qjmed/91.4.291. QJM. 1998. PMID: 9666952 Clinical Trial.
Effects of atorvastatin and simvastatin on low-density lipoprotein subfraction profile, low-density lipoprotein oxidizability, and antibodies to oxidized low-density lipoprotein in relation to carotid intima media thickness in familial hypercholesterolemia.
van Tits LJ, Smilde TJ, van Wissen S, de Graaf J, Kastelein JJ, Stalenhoef AF. van Tits LJ, et al. J Investig Med. 2004 Apr;52(3):177-84. doi: 10.1136/jim-52-03-32. J Investig Med. 2004. PMID: 15222407 Clinical Trial.
Atorvastatin.
Hyatt PJ. Hyatt PJ. Br J Hosp Med. 1997 Oct 1-14;58(7):333-6. Br J Hosp Med. 1997. PMID: 9509055 Review. No abstract available.
[Substantiation of increasing doses of statins in clinical practice].
Susekov AV. Susekov AV. Ter Arkh. 2001;73(4):76-80. Ter Arkh. 2001. PMID: 11494456 Review. Russian. No abstract available.

See all similar articles

Cited by

Should pediatric patients with hyperlipidemia receive drug therapy?
Bhatnagar D. Bhatnagar D. Paediatr Drugs. 2002;4(4):223-30. doi: 10.2165/00128072-200204040-00002. Paediatr Drugs. 2002. PMID: 11960511 Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science